Compare
BioMarin Pharmaceutical vs Gilead Sciences (BMRN vs GILD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year BioMarin Pharmaceutical (BMRN) returned +6.1% and Gilead Sciences (GILD) +36.1%; so far this year the figures are -5.7% and +36.0%.
Gilead Sciences is the larger company by market value, about 19.1 times the size of BioMarin Pharmaceutical.
Revenue grew +18.1% at BMRN and +6.5% at GILD over the last year.
BMRN pays no dividend. GILD yields 1.95%.
Data as of the latest close. Not investment advice.
Relative performance
| BMRN | GILD | |
|---|---|---|
| Price | $56.03 | $166.89 |
| 1-day | -0.16% | -0.41% |
| YTD | -5.72% | +35.97% |
| 1 year | +6.12% | +36.15% |
| 3 years | -33.31% | +108.12% |
| Market cap | $10.8B | $207.0B |
| P/E | — | — |
| P/S | 2.97 | 6.68 |
| P/B | 1.73 | 15.87 |
| Revenue growth | +18.10% | +6.50% |
| EPS growth | -103.70% | -149.00% |
| Gross margin % | 76.0 | 79.9 |
| Net margin % | -0.5 | -12.5 |
| ROE % | -0.3 | -29.6 |
| Debt / equity | 0.67 | 2.01 |
| FCF yield % | 5.1 | 6.7 |
| Dividend yield % | — | 1.95 |
| Beta | 0.34 | 0.37 |
| RSI (14) | 45.2 | 60.2 |
| Technical rating |